Randomized, double-blind, placebo-controlled, Phase 3, parallel-group study with optional open-label extension.
Treatment of tobacco dependence by providing relief of nicotine withdrawal symptoms including cravings (see section 5.1), thereby facilitating smoking cessation or temporary smoking reduction in smokers motivated to quit smoking. Permanent cessation of tobacco use is the eventual objective. Patient counselling and support normally improve the success rate.
NiQuitin Extra Fresh Mint Gum relieves and/or prevents craving and nicotine withdrawal symptoms associated with tobacco dependence. It is indicated to aid smokers wishing to quit or reduce prior to quitting, to assist smokers who are unwilling or unable to smoke, and as a safer alternative to smoking for smokers and those around them. This product is indicated in pregnant and lactating women making a quit attempt. NiQuitin Extra Fresh Mint Gum should preferably be used in conjunction with a behavioural support programme.
For inhibition of the formation of dental plaque. As an aid in the treatment and prevention of gingivitis and in the maintenance of oral hygiene, particularly in situations where tooth brushing cannot be adequately employed (e.g. following oral surgery, in mentally or physically handicapped patients). Also for use in a post-peridontal surgery or treatment* regimen to promote gingival healing. *NB: Use as part of a post-periodontal treatment regimen has only been adequately studied over the short term and following standard root surface instrumentation. It is useful in the management of aphthous ulceration and oral candidal infections (e.g. denture stomatitis and thrush).
For the relief of pain, discomfort and inflammation caused by common mouth ulcers, cold sores, denture and sore spots, as well as mouth ulcers, and sore spots due to orthodontic devices. To help to fight minor mouth infection and aid healing of sore spots and ulcers due to dentures and orthodontic devices.
Treatment of symptoms resulting from the reflux of acid, bile and pepsin into the oesophagus such as acid regurgitation, heartburn and indigestion, for example following meals or during pregnancy, and for symptoms of excess stomach acid (hyperacidity). Can also be used to treat the symptoms of gastro-oesophageal reflux during concomitant treatment with or following withdrawal of acid suppressing therapy.
Nicotine Perrigo 2mg Lozenges are indicated for the treatment of tobacco dependence by relieving nicotine withdrawal symptoms including cravings, associated with smoking cessation. Permanent cessation of tobacco use is the eventual objective. Nicotine Perrigo 2mg Lozenges should preferably be used in conjunction with a behavioural support programme.
NiQuitin Minis 1.5 mg Lozenges relieve and/or prevent craving and nicotine withdrawal symptoms associated with tobacco dependence. They are indicated to aid smokers wishing to quit or reduce prior to quitting, to assist smokers who are unwilling or unable to smoke, and as a safer alternative to smoking for smokers and those around them. NiQuitin Minis 1.5 mg Lozenges are indicated in pregnant and lactating women making a quit attempt.NiQuitin Minis Mint 1.5 mg Lozenges should preferably be used in conjunction with a behavioural support programme.